Tranexamic Acid is an antifibrinolytic agent used mainly in the treatment and prophylaxis of haemorrhage associated with excessive fibrinolysis. It is given by mouth, by slow intravenous injection, or limited to gastro-intestinal disturbances, hypotension has occured, particularly afer rapid intravenous infusion.
Tranexamic Acid appears to be well tolerated.It can produce dose-related gastro-intestinal disturbances. Hyportension has occured, particularly after rapid intravenous administration. Thrombotic complications have been reported in patients receiving Tranexamic Acid, but these are usually a consequence of its inappropriate use.
Should not be used in patients with active intravascular clotting because of the risk of thrombosis. Patients with a predisposition to thrombosis are also at rish it given antibrinolytic therapy. Haemorrhage due to disseminated intravascular coaguflation should therefore not be treated not be treated with antifibrinclytic compounds unless the condition is predominantly due to disturbances in fibrinolytic mechanisms; Tranexamic Acid has been used when the latter conditions are met, but with careful monitoring and anticoagulant cover.
Tranexamic Acid is rapidly absorbed from the gastrointestinal tract, absorption is 30 to 50%. It is widely distributed throughout the body, diffuses acroos the placenta, and has been detected in breast milk. It has a plasma elimination half-life of about 2 hours. It is excreted in the urine mainly as unchanged drug.
It is used in the treatment and prophylaxis of haemorrhage associated with excessive librinolysis. It is also used in the prophylaxis of hereditary angloedema.
Usual adult dose: 1 to 1.5 g (for 15 to 25 mg per kg body weight). 2 to 4 times daily, or as prescribed by the physician.
Foods, Drugs, Devices and Cosmetics Act prohibits dispensing without prescription.
Blister Pack x 10′s (Box of 100′s)
Store at temperatures not exceeding 30 degree Celsius.